10-Q: Heron Therapeutics Reports Increased Revenue in Q2 2024, Despite Net Loss

Heron Therapeutics saw a rise in product sales during the second quarter of 2024, but still experienced a net loss.

Summary

• Heron Therapeutics reported a net product sales increase to $36.0 million for the three months ended June 30, 2024, compared to $31.8 million for the same period in 2023.
• For the six months ended June 30, 2024, net product sales reached $70.7 million, up from $61.4 million in the prior year.
• The company experienced a net loss of $9.2 million for the quarter and $12.4 million for the six-month period, which is an improvement compared to the net losses of $42.1 million and $74.8 million for the same periods in 2023.
• Cash, cash equivalents, and short-term investments totaled $67.3 million as of June 30, 2024.
• Management believes that current resources will be sufficient to meet anticipated cash requirements for at least the next twelve months.
• The company's operating expenses decreased due to restructuring efforts implemented in 2023.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to increased sales and reduced losses, but tempered by ongoing patent litigation and the fact that the company is still not profitable. The company's strategic partnerships and potential product approvals are positive indicators.

Positives

• Net product sales increased year-over-year for both the three and six-month periods ending June 30, 2024.
• The company's net loss significantly decreased compared to the same periods in the previous year.
• The company has sufficient cash and investments to meet its anticipated cash requirements for at least the next twelve months.
• The partnership with CrossLink Life Sciences is expected to expand the sales network for ZYNRELEF.
• The potential approval of the vial access needle for ZYNRELEF could simplify preparation and reduce withdrawal time.

Negatives

• The company continues to experience a net loss, despite increased sales.
• The company is involved in multiple patent litigations, which could impact future revenue.
• The company has incurred charges related to inventory write-offs.

Risks

• The company faces intense competition from other companies developing products for pain management and the prevention of nausea and vomiting.
• The company's ability to achieve profitability is uncertain.
• The company is subject to risks related to commercializing its products, including market acceptance and pricing.
• The company is involved in ongoing patent litigation, which could impact its intellectual property rights and future revenue.
• The company relies on third-party contract manufacturers, which could lead to supply chain issues.

Future Outlook

Management believes that the company's cash, cash equivalents, short-term investments, and working capital facility will be sufficient to meet the company's anticipated cash requirements for at least the next twelve months. The company anticipates the vial access needle for ZYNRELEF to be available in the fourth quarter of this year, pending FDA approval.

Management Comments

• Management believes that the Company's cash, cash equivalents and short-term investments will be sufficient to meet the Company's anticipated cash requirements for a period of at least one year from the date this Quarterly Report on Form 10-Q is filed with the U.S. Securities and Exchange Commission (SEC).
• Management believes that the company's cash, cash equivalents, short-term investments and working capital facility, will be sufficient to meet the company's anticipated cash requirements for a period of at least the next twelve months from the date this Quarterly Report on Form 10-Q is filed with the SEC.

Industry Context

The report highlights Heron's efforts to compete in the postoperative pain and CINV/PONV markets, which are characterized by numerous competitors and generic alternatives. The company's focus on innovative drug delivery technologies and unique formulations, such as extended-release products, is a key differentiator. The ongoing patent litigations reflect the competitive landscape and the importance of intellectual property protection in the pharmaceutical industry.

Comparison to Industry Standards

• Heron's ZYNRELEF competes with products like Pacira BioSciences' EXPAREL, a liposomal bupivacaine, and generic bupivacaine, with ZYNRELEF aiming to differentiate itself through its dual-acting, extended-release formulation.
• APONVIE competes with generic ondansetron, the standard of care for PONV, and Eagle Pharmaceuticals' BARHEMSYS, with APONVIE being the first and only intravenous formulation of a substance P/neurokinin-1 (NK1) receptor antagonist.
• CINVANTI competes with Merck's EMEND IV (fosaprepitant) and other NK1 receptor antagonists, with CINVANTI being the first IV formulation to directly deliver aprepitant without synthetic surfactants like polysorbate 80.
• SUSTOL competes with other 5-HT3 receptor antagonists like palonosetron and generic ondansetron, with SUSTOL being the first extended-release 5-HT3 receptor antagonist approved for both MEC and AC combination chemotherapy regimens.
• The company's financial performance is being compared to previous periods, with a focus on improved sales and reduced losses, which is a common metric for evaluating growth-stage pharmaceutical companies.

Legal Proceedings

• The company is involved in patent litigation with Fresenius Kabi regarding CINVANTI, with a partial summary judgment of infringement granted to Heron.
• The company is involved in patent litigation with Mylan regarding both CINVANTI and APONVIE, with a bench trial scheduled for May 19, 2025.
• The company is involved in patent litigation with Slayback Pharma regarding CINVANTI, with the case being transferred to the U.S. District Court for the District of Delaware.

Stakeholder Impact

• Shareholders may be encouraged by the increased sales and reduced losses, but concerned about the ongoing patent litigation.
• Employees may be impacted by the restructuring efforts implemented in 2023.
• Customers (healthcare providers and hospitals) will benefit from the availability of Heron's products.
• Suppliers may be impacted by the company's reliance on third-party contract manufacturers.
• Creditors may be impacted by the company's debt obligations.

Next Steps

• The company will continue to commercialize its existing products.
• The company will focus on expanding the sales network for ZYNRELEF through its partnership with CrossLink.
• The company will await the FDA's decision on the prior approval supplement for the vial access needle for ZYNRELEF.
• The company will continue to defend its intellectual property rights in ongoing patent litigations.

Key Dates

Keywords

Heron Therapeutics, ZYNRELEF, APONVIE, CINVANTI, SUSTOL, postoperative pain, chemotherapy-induced nausea and vomiting, PONV, pharmaceuticals, biotechnology